Literature DB >> 34057010

Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes.

J S Westerdahl1, K B Nusbaum2, C G Chung3,4, B H Kaffenberger3, A G Ortega-Loayza5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34057010     DOI： 10.1080/09546634.2021.1937475

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN： 0954-6634            Impact factor:   3.359


× No keyword cloud information.
  3 in total

1.  Modified dose of guselkumab for treatment of pyoderma gangrenosum.

Authors:  Ashley M Reese; Katherine Erickson; Katherine B Reed; Alex G Ortega-Loayza
Journal:  JAAD Case Rep       Date:  2022-01-06

2.  Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52-week phase 3 open-label study.

Authors:  Kenshi Yamasaki; Keiichi Yamanaka; Yiwei Zhao; Shunsuke Iwano; Keiko Takei; Koji Suzuki; Toshiyuki Yamamoto
Journal:  J Dermatol       Date:  2022-03-03       Impact factor: 3.468

Review 3.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.